Efficacy and safety of naftopidil for treatment of distal ureteral calculi: a systematic review and meta-analysis

GAO Hao; NING Songyi; LIU Guang; HU Yougen; and TANG Yuanjie

PDF(1313 KB)

Medical Journal of the Chinese People Armed Police Forces ›› 2016, Vol. 27 ›› Issue (9) : 895-899.

ORIGINAL ARTICLES

Efficacy and safety of naftopidil for treatment of distal ureteral calculi: a systematic review and meta-analysis

GAO Hao¹, NING Songyi², LIU Guang², HU Yougen², and TANG Yuanjie²

Author information +

History +

Abstract

Objective To access the efficacy and safety of naftopidil in medical expulsive therapy of distal ureteral calculi. Methods A systematic search was performed in Pubmed, Cochrane Library, CNKI, Wanfang database and VIP database to identify RCTs that compared naftopidil and other therapy for distal ureteral calculi. Two authors independently assessed study quality and extracted data. All data were analyzed using RevMan5.0. Results 11 studies with a total of 983 patients met the inclusion criteria. There was a significant overall benefit for stone expulsion rate(RR=1.63, 95%CI 1.32-2.03, P＜0.01)and stone expulsion time(WMD=-2.83, 95% CI -3.75--1.92, P＜ 0.01)in naftopidil group compared with watching waiting group. Compared with α_1A adrenergic receptor blockers group, there was no statistically significant differences in expulsion rate(RR=0.97, 95% CI 0.78-1.20, P=0.76)and stone expulsion time(WMD=0.15, 95%CI -0.40-0.69, P=0.59). But naftopidil provided a significantly lower side effects rate(RR=0.52, 95%CI 0.27-0.98, P=0.04). Conclusions Naftopidil can effectively promote the expulsion of distal ureteral calculi. Compared with α_1A-adrenergic receptor blockers, there are no statistically significant differences in expulsion rate and stone expulsion time, but with a significantly lower side effects rate.

Key words

distal ureteral calculi / naftopidil / α_1D adrenergic receptor blockers / medical expulsive therapy / Meta-analysis

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

GAO Hao, NING Songyi, LIU Guang, HU Yougen, and TANG Yuanjie. Efficacy and safety of naftopidil for treatment of distal ureteral calculi: a systematic review and meta-analysis[J]. Medical Journal of the Chinese People Armed Police Forces. 2016, 27(9): 895-899

References

[1] 刘志华, 周祥福. 输尿管下段结石的治疗进展[J]. 中华腔镜泌尿外科杂志(电子版),2010, 4(1):76-78.
[2] Wook K D, Gorbachinsky I, Gutierrez J. Medical expulsive therapy [J]. Indian J Urol, 2014, 30(1): 60-64.
[3] Jadal A R, Moore R A,Carroll D,et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?[J]. Control Clin Trials, 1996, 17(1): 1-12.
[4] Lu J L, Tang Q L, De L F,et al. Naftopidil and tolterodine in the medical expulsive therapy for intramural ureteral stones: a prospective randomized study[J]. Urol Res, 2012, 40(6): 757-762.
[5] Lv J L,Tang Q L.Comparative evaluation of efficacy of use of naftopidil and/or celecoxib for medical treatment of distal ureteral stones[J]. Urolithiasis, 2014,42(6): 541-547.
[6] Kumar S, Kurdia K C,Ganesamoni R,et al. Randomized controlled trial to compare the safety and efficacy of naftopidil and tamsulosin as medical expulsive therapy in combination with prednisolone for distal ureteral stones [J]. Korean J Urol, 2013, 54(5):311-315.
[7] Tsuzaka Y, Matsushima H,Kaneko T,et al. Naftopidil vs silodosin in medical expulsive therapy for ureteral stones: a randomized controlled study in Japanese male patients[J]. Int J Urol, 2011,18(11): 792-795.
[8] Zhou S G, Lu J L, and Hui J H.Comparing efficacy of alpha1D-receptor antagonist naftopidil and alpha1A/D-receptor antagonist tamsulosin in management of distal ureteral stones[J]. World J Urol, 2011, 29(6): 767-771.
[9] 王浩敏,王芳,李永生,等.萘哌地尔治疗输尿管下段结石的疗效观察[J].药物与临床,2010,17(31):51-52.
[10] 张忠林,李火金,史明,等.萘哌地尔治疗输尿管下段结石的疗效观察[J].深圳中西医结合杂志,2009,19(1):34-36.
[11] 金晓华,王竞,范波,等.萘哌地尔治疗输尿管下段结石的临床研究[J].现代中西医结合杂志, 2012, 21(30): 3369-3371.
[12] Kohjimoto Y, Hagino K, Ogawa T,et al. Naftopidil versus flopropione as medical expulsive therapy for distal ureteral stones: results of a randomized, multicenter, doubleblind, controlled trial [J]. 2015, 33(12): 2125-2129.
[13] Sun X Z, Lei H, Wei H G,et al. Efficacy of selective 1D-blocker naftopidil as medical expulsive therapy for distal ureteral stones [J]. J Urol, 2009,181(4):1716-1720.
[14] 冉清,窦科,熊伟.萘哌地尔治疗输尿管下段结石的临床评价[J].四川医学, 2008, 29(5): 540-541.
[15] Malin J M, Deane R F, Boyarsky S. Characterisation of adrenergic receptors in human ureter [J]. Br J Urol, 1970, 42(2): 171-174.
[16] Dellabella M, Milanese G, Muzzonigro G. Efficacy of tamsulosin in the medicalmanagement of juxtavesical ureteral stones [J]. J Urol, 2003, 170(6pt1): 2202-2205.
[17] Itoh Y, Kojima Y, Yasui T, et al. Examination of alpha 1 adrenoceptor subtypes in the human ureter [J]. Int J Urol, 2007, 14(8):749-753.
[18] Takei R, Ikegaki I, Shibata K,et al. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors [J]. Jpn J Pharmacol, 1999, 79(4): 447-454.
[19] Ohgaki K, Horiuchi K, Hikima N,et al. Facilitation of expulsion of ureteral stones by addition of α1-blockers to conservative therapy [J].Scand J Urol Nephrol, 2010,44(6):420-424.
[20] Sasaki S, Tomiyama Y, Kobayashi S,et al. Characterization of α1-adrenoceptor subtypes mediating contraction in human isolated ureters [J]. Urology, 2011,77(3):762.e13-17.
[21] Tatemichi S, Kobayashi K, Maezawa A,et al. Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin(KMD-3213)[J]. Yakugaku zasshi, 2006,126: 209-216.
[22] Take H, Shibata K, Awaji T,et al. Vascular alpha1-adrenoceptor subtype selectivity and alpha1-blocker-induced orthostatic hypotension [J]. Jpn J Pharmacol,1998, 77(1): 61-70.
[23] Bozkurt O, Demir O, Sen V,et al. Silodosin causes impaired ejaculation andenlargement of seminal vesicles in sexually active men treated for lower urinary tract symptoms suggestive of benign prostatic hyperplasia[J]. Urology, 2015, 85(5):1085-1089.